218 related articles for article (PubMed ID: 26156055)
21. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach.
Chen X; Tong Y; Shi Z; Chen H; Yang Z; Wang Y; Chen L; Yu J
BMC Neurol; 2019 Jan; 19(1):6. PubMed ID: 30616515
[TBL] [Abstract][Full Text] [Related]
23. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.
La Corte E; Younus I; Pivari F; Selimi A; Ottenhausen M; Forbes JA; Pisapia DJ; Dobri GA; Anand VK; Schwartz TH
Pituitary; 2018 Dec; 21(6):571-583. PubMed ID: 30187175
[TBL] [Abstract][Full Text] [Related]
24. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
Erfurth EM
J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
[TBL] [Abstract][Full Text] [Related]
25. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
[TBL] [Abstract][Full Text] [Related]
26. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
27. Genetic basis of calcifying cystic odontogenic tumors.
Yukimori A; Oikawa Y; Morita KI; Nguyen CTK; Harada H; Yamaguchi S; Kayamori K; Yamaguchi A; Ikeda T; Sakamoto K
PLoS One; 2017; 12(6):e0180224. PubMed ID: 28658279
[TBL] [Abstract][Full Text] [Related]
28. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
29. Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation.
Hara T; Akutsu H; Takano S; Kino H; Ishikawa E; Tanaka S; Miyamoto H; Sakamoto N; Hattori K; Sakata-Yanagimoto M; Chiba S; Hiyama T; Masumoto T; Matsumura A
J Neurosurg; 2018 Aug; 131(1):217-226. PubMed ID: 30074466
[TBL] [Abstract][Full Text] [Related]
30. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.
Prieto R; Pascual JM
Pituitary; 2018 Aug; 21(4):431-442. PubMed ID: 29700680
[TBL] [Abstract][Full Text] [Related]
31. Craniopharyngioma in Pediatrics and Adults.
Piloni M; Gagliardi F; Bailo M; Losa M; Boari N; Spina A; Mortini P
Adv Exp Med Biol; 2023; 1405():299-329. PubMed ID: 37452943
[TBL] [Abstract][Full Text] [Related]
32. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
33. Genomic drivers in craniopharyngiomas: Analysis of the AACR project GENIE database.
Lehrich MB; Tong CLC; Hsu PKF; Kuan CE
Childs Nerv Syst; 2024 Jun; 40(6):1661-1669. PubMed ID: 38421446
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma.
Kim JH; Paulus W; Heim S
J Neurooncol; 2015 May; 123(1):189-91. PubMed ID: 25820214
[No Abstract] [Full Text] [Related]
35. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
36. Erratum to: Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2016 Feb; 19(1):113. PubMed ID: 26450712
[No Abstract] [Full Text] [Related]
37. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
[TBL] [Abstract][Full Text] [Related]
38. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
39. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
40. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]